Wireless Assessment of Respiratory and Circulatory Distress - Continuous Glucose Monitoring

CompletedOBSERVATIONAL
Enrollment

70

Participants

Timeline

Start Date

June 26, 2020

Primary Completion Date

February 28, 2021

Study Completion Date

February 28, 2021

Conditions
HypoglycemiaPerioperative Complication
Interventions
OTHER

Continuous vital signs and glucose monitoring

"The patients will have the following parameters and vital signs continuously monitored using wireless equipment:~* Glucose measurements (quasi-continuous, every 5 minutes)~* Heart rate~* Heart rhythm (single-lead ECG; quasi-continuous, 10 seconds every minute)~* Signs of cardiac ischemia (single-lead ECG; quasi-continuous, 10 seconds every minute)~* Respiration rate~* Oxygen saturation of arterial hemoglobin (%SpO2)~* Perfusion index (ratio of the pulsatile blood flow to the non-pulsatile or static blood in peripheral tissue)~* Blood pressure (quasi-continuous; every 30-60 minutes)~* Skin temperature~* Electrodermal activity~* Ambulatory activity (accelerometry)"

Trial Locations (2)

2100

Rigshospitalet, Copenhagen

2400

Bispebjerg Hospital, Copenhagen

All Listed Sponsors
collaborator

Rigshospitalet, Denmark

OTHER

lead

University Hospital Bispebjerg and Frederiksberg

OTHER

NCT04473001 - Wireless Assessment of Respiratory and Circulatory Distress - Continuous Glucose Monitoring | Biotech Hunter | Biotech Hunter